Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care Lamzede Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Lamzede (velmanase alfa) Medical Benefit Medication Utilization Policy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage criteria, authorization, and coding guidance for velmanase alfa (Lamzede) for treatment of alpha-mannosidosis; applies to providers requesting prior authorization from the payer for affected members.

    Policy Summary
    PayerCommunity-Care
    PolicyLamzede (velmanase alfa) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewSep 1, 2023
    Next Review DateSep 1, 2024
    Key ActionObtain prior authorization with diagnostic confirmation (enzyme assay showing alpha-mannosidase activity < 10% of normal) and specialist prescribing or consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearauthorization period if approved
    Nonequantity limit for alpha-mannosidosis
    <10% enzymediagnostic threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Sept 2023
    last reviewed

    Coverage criteria for Lamzede (velmanase alfa)

    inv-01: Initial Therapy

    Covered when ALL of the following are met

    Initial Approval for Alpha-mannosidosis: 1) Diagnosis of alpha-mannosidosis; 2) Documentation of enzyme assay demonstrating alpha-mannosidase activity < 10% of normal activity; 3) Prescribed by, or in consultation with, a specialist familiar with the treatment of lysosomal storage disorders

    inv-02: Continuation Therapy

    Covered when ALL of the following are met

    Continuation Approval for Alpha-mannosidosis: 1) Diagnosis of alpha-mannosidosis; 2) Member is being monitored, has benefited from therapy, and is appropriate to continue therapy with velmanase alfa

    Approval period: up to 1 year

    Coverage for velmanase alfa (Lamzede) for treatment of alpha-mannosidosis is provided when all specified criteria are met. For initial therapy, the member must have: (1) a documented diagnosis of alpha-mannosidosis; (2) diagnostic confirmation with an enzyme assay showing alpha-mannosidase activity < 10% of normal; and (3) the medication prescribed by, or in consultation with, a specialist experienced in management of lysosomal storage disorders. Prior authorization is required and, if approved, coverage is granted for up to 1 year.

    For continuation therapy, coverage is allowed when all continuation criteria are met: (1) diagnosis of alpha-mannosidosis is documented; and (2) the member is being actively monitored, has demonstrated benefit from velmanase alfa, and is considered appropriate to continue therapy. Continuation authorizations are also issued for up to 1 year when these conditions are satisfied.

    Billing and coding

    Applicable HCPCS CodesHCPCS
    J0217
    Enzyme activity threshold
    Enzyme activity threshold< 10% of normal activity
    Measurement methodAlpha-mannosidase enzyme assay
    Use for coverage decisionsRequired for diagnostic confirmation and initial approval

    What providers must do / watch for

    Prior Authorization

    Prior authorization required with diagnostic confirmation and specialist involvement

    Prior authorization is required for velmanase alfa (Lamzede). Submit documentation of diagnostic confirmation — an enzyme assay demonstrating alpha-mannosidase activity < 10% of normal — and evidence that the drug was prescribed by, or in consultation with, a specialist familiar with lysosomal storage disorders. Approvals, when granted, are for up to 1 year.

    • Applicable HCPCS code: J0217
    Note

    Confirm specialist involvement and enzyme assay before submission

    Ensure the request includes specialist involvement (prescribed by or in consultation with a specialist familiar with lysosomal storage disorders) and the required enzyme assay result; missing either may lead to denial.

    • Prescriber is a specialist or consultation documentation is provided
    • Enzyme assay result showing alpha-mannosidase activity < 10% of normal

    Background and clinical context

    Alpha-mannosidosis is a rare lysosomal storage disorder treated with enzyme replacement therapy such as velmanase alfa (Lamzede). Diagnosis is confirmed by measurement of alpha-mannosidase enzyme activity; the policy requires an enzyme assay demonstrating alpha-mannosidase activity < 10% of normal for diagnostic confirmation. Management and prescribing should involve a specialist familiar with lysosomal storage disorders to ensure appropriate evaluation and monitoring.

    Definitions and thresholds

    Enzyme assay threshold
    Diagnostic requirementDiagnostic confirmation requires an enzyme assay demonstrating alpha-mannosidase activity < 10% of normal activity.
    Context of useRequired as part of documentation submitted for prior authorization and initial approval
    Associated diagnosisAlpha-mannosidosis

    Initial therapy criteria for velmanase alfa

    inv-13: Initial Therapy

    Initial coverage criteria for velmanase alfa

    Initial: Diagnosis of alpha-mannosidosis; enzyme assay demonstrating alpha-mannosidase activity < 10% of normal; prescribed by or in consultation with specialist familiar with lysosomal storage disorders

    Continuation therapy criteria for velmanase alfa

    inv-14: Continuation Therapy

    Continuation of velmanase alfa for alpha-mannosidosis

    Continuation: Diagnosis of alpha-mannosidosis; member is being monitored and has benefited from therapy and is appropriate to continue velmanase alfa; authorization granted up to 1 year

    Quantity limits and administration

    Lamzede (velmanase alfa) — Quantity limits
    DrugLamzede (velmanase alfa)
    Quantity limitNone
    ApplicabilityApplies to treatment of alpha-mannosidosis under this policy

    Site of care considerations

    Note

    No specific site‑of‑care restriction listed

    No site‑of‑care restriction specified in the policy; providers should follow usual billing and placement practices for therapeutic infusions or administrations of velmanase alfa.

    Policy Summary
    PayerCommunity-Care
    PolicyLamzede (velmanase alfa) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewSep 1, 2023
    Next Review DateSep 1, 2024
    Key ActionObtain prior authorization with diagnostic confirmation (enzyme assay showing alpha-mannosidase activity < 10% of normal) and specialist prescribing or consultation.
    SourceLink
    On This Page
    Coverage criteria for Lamzede (velmanase alfa)Billing and codingWhat providers must do / watch forBackground and clinical contextDefinitions and thresholdsInitial therapy criteria for velmanase alfaContinuation therapy criteria for velmanase alfaQuantity limits and administrationSite of care considerations
    Documentation Required

    Required documentation for prior authorization

    Documentation submitted with the authorization request must include a diagnosis of alpha-mannosidosis and the enzyme assay demonstrating alpha-mannosidase activity < 10% of normal; note whether the medication was prescribed by, or in consultation with, a specialist experienced in lysosomal storage disorders.

    • Diagnosis of alpha-mannosidosis
    • Enzyme assay result documenting alpha-mannosidase activity < 10% of normal
    • Record of specialist prescribing or consultation
    Denial Risk

    Denial triggers: missing diagnostic proof or specialist involvement

    Requests missing the required diagnostic documentation (enzyme assay showing alpha-mannosidase activity < 10% of normal) or lacking specialist involvement (no evidence that a specialist prescribed or was consulted) may be denied.

    • Absence of enzyme assay result demonstrating < 10% activity
    • No documentation of specialist prescribing or consultation